Device Trial Radar · NCT06436222
Effectiveness of HVNI in Preterm Infants With Moderate Respiratory Distress
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 20, 2024
Primary completion
Dec 31, 2024
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- Universitas IndonesiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 28 weeks, up to 32 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Neonatal respiratory distress is a common problem in preterm infants. The application of CPAP is widely used in neonatal units as a primary mode of respiratory support for respiratory distress. However, discomfort, nasal injuries, and fixation difficulties have been reported as obstacles when applying CPAP. High velocity nasal insufflation (HVNI) may serve as an alternative to CPAP. Trials are needed to evaluate the effectiveness of HVNI in reducing the incidence of respiratory distress. The aim of this study is to compare the clinical effectiveness and safety of HVNI as an alternative therapy to CPAP in premature infants with moderate respiratory distress. This study was originally designed as a non-inferiority randomized controlled trial. Due to feasibility constraints, the protocol was amended prior to completion of recruitment, and the study was reclassified as a pilot randomized controlled trial to assess feasibility and safety outcomes of HVNI compared to CPAP. The subjects were randomly allocated to receive either HVNI or CPAP according to the study protocol. They were randomly assigned using blocks of four. The completion of HVNI therapy was determined by therapeutic failure within 72 hours following enrollment, indicated by the need for intubation.
Conditions
- Respiratory Distress, Newborn
Interventions
HVNIDevice
The infant was given therapy using HVNI with an initial flow of 6 L/min. Inspiratory fraction of oxygen (FiO2) started with 30% following the SpO2 target. The maximum flow is 8L/min. FiO2 can be increased by 5% until the target SpO2 is reached.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of HVNI to prevent intubation within 72 hoursTime frame: Intubation rates within 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.